RxDoctor Payments Data

Ryan Lange, MD

Ophthalmology · Evanston, ILNPI 1679997712

Payments from drug & device makers

$734in general payments, 2019–2025

Across 15 payments — averaging $48.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$283
  • Johnson & Johnson Surgical Vision, Inc.$159
  • Kala Pharmaceuticals, Inc.$152
  • Sun Pharmaceutical Industries Inc.$56
  • Sight Sciences, Inc.$49
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$22
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$734100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$734 in reported general payments places this provider in the 40th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$135,286
Medicare patients
459
Services billed
1,020

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine35$32,142
Loteprednol Etabonate50$5,313
Prednisolone Acetate76$2,443
Timolol Maleate15$1,820
Latanoprost125$1,173
Fluorometholone12$721
Doxycycline Hyclate16$472
Brimonidine Tartrate23$427
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha30$285
Ketorolac Tromethamine25$214
ErythromycinErythromycin Base16$192

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$22$5,31350 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in Evanston

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →